Reported Earlier, Terns Pharmaceuticals Unveils Preclinical Data on Obesity Treatment at ADA 2024
Reported Earlier, Terns Pharmaceuticals Unveils Preclinical Data on Obesity Treatment at ADA 2024
Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that preclinical data supporting TERN-501, a highly selective thyroid hormone receptor beta (THR-β) receptor agonist, in combination with a GLP-1 receptor agonist for obesity will be highlighted in a poster presentation at the American Diabetes Association (ADA) 84th Scientific Sessions, taking place June 21 – 24, 2024 in Orlando, FL.
Terns Pharmaceuticals, Inc.（“Terns”或“公司”）（納斯達克：TERN）是一家臨床階段的生物製藥公司，開發一系列小分子藥物候選產品以治療嚴重疾病，包括腫瘤和肥胖症。今天宣佈，在2024年6月21日至24日於佛羅里達州奧蘭多舉行的美國糖尿病協會（ADA）第84屆科學會議上，將重點展示支持聯合GLP-1受體激動劑治療肥胖症的高度選擇性甲狀腺激素受體β（THR-β）受體激動劑TERN-501的臨床前數據的海報報告。